Overview

PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood

Status:
Completed

Trial end date:
2016-04-30

Target enrollment:

Participant gender:

Summary

In this prospective study is to examine whether the use of everolimus in patients after allogeneic SCT as part of GVHD prophylaxis for a further review in clinical studies is appropriate.

Phase:

Phase 2

Details

Lead Sponsor:

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Collaborators:

ClinAssess GmbH
Deutsche Klinik fuer Diagnostik

Treatments:

Everolimus
Sirolimus